Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Foliglurax on CYP450 Substrates
NCT04275115Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Feb 2020
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of foliglurax in Parkinson's disease (PD), sponsored by Lundbeck. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Zero to Infinity at Day 20 and Maximum Observed Plasma Concentration at Day 20. Started Feb 2020; status: completed.
02
Drugs
foliglurax
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04275115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04275115.